Characterization of genome integrity for oversized recombinant AAV vector
- PMID: 19904236
- PMCID: PMC2803017
- DOI: 10.1038/mt.2009.258
Characterization of genome integrity for oversized recombinant AAV vector
Abstract
Application of recombinant adeno-associated virus (rAAV) in gene therapy has been limited by its packaging capacity. Recent studies suggested that rAAV could achieve persistent transgene expression beyond 4.7-kb packaging limit. To clarify the mechanism leading to transgene expression from oversized rAAV vector, we constructed a series of rAAV vectors with genomes ranging from 2.9 to 7.2 kb. A plasmid replication origin and an ampicillin-resistant marker were included in the vector to facilitate the recovery of circularized, post-transduction AAV genome. Southern dot-blot analysis and silver staining confirmed that rAAVs could be produced at varying vector size. However, the vector yields decreased approximately tenfold for oversized vectors as compared to regular ones. Alkaline Southern blot hybridization suggested that the packaged genomes for oversized vectors were truncated. In the cells transduced by the above vectors, circularized rAAV monomers could be rescued at 24 hours after infection. Few recovered AAV genomes were >5 kb regardless of the initial vector size. In mice receiving the above vectors, larger circularized rAAV genomes could be recovered for oversized vectors at day 21 after vector administration. Our studies suggested that the partially packaged rAAV sequences may complement each other to restore full expression cassette.
Figures
Comment in
-
Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus.Mol Ther. 2010 Jan;18(1):6-8. doi: 10.1038/mt.2009.280. Mol Ther. 2010. PMID: 20048740 Free PMC article. No abstract available.
References
-
- Muzyczka N., and , Berns KI. Fields Virology. 4th edn. Lippincott Williams & Wilkins: Philadelphia; 2002. Parvoviridae: the viruses and their replication. In: Knipe, DM and Howley, PM (eds) pp. 2327–2360.
-
- Ferrari FK, Xiao X, McCarty D., and , Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med. 1997;3:1295–1297. - PubMed
-
- Samulski RJ. AAV vectors, the future workhorse of human gene therapy. Ernst Schering Res Found Workshop. 2003. pp. 25–40. - PubMed
-
- Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56–63. - PubMed
-
- Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3:306–312. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
